Management of severe internal (life- or limb-threatening) bleeding in acquired hemophilia.

* aPCC are used as first line therapy by some hematologists, but it is generally preferable to avoid human plasma-derived products where there are effective alternatives, especially in previously unexposed patients. Concurrent use of antifibrinolytic agents with aPCC should be avoided because of the risk of thrombosis.

Abbreviations: FVIII, factor VIII; rFVIIa, recombinant activated factor VIIa; aPCC, activated prothrombin complex concentrate